Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03679767 · ClinicalTrials.gov registry record · Phase 2
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
A Phase 2 study of Metastatic Melanoma and Metastatic Non Small Cell Lung Cancer, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
- 20
- Study locations
NCT03679767 is a Phase 2 study of Metastatic Melanoma and Metastatic Non Small Cell Lung Cancer that has completed, run by Incyte Corporation. The registered enrollment target is 121 participants, above the 82-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (48% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT03679767, a Phase 2 study of Metastatic Melanoma and Metastatic Non Small Cell Lung Cancer, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.
Conditions Studied
Interventions
- DRUG Retifanlimab
Study Locations (20)
Texas
- Texas Oncology Surgical Specialists - Austin Central - Austin
- Coastal Bend Cancer Center - Corpus Christi
- AIM Trials, LLC - Plano
- Texas Oncology - San Antonio Northeast - San Antonio
- Oncology and Hematology Associates of Southwest Virginia, Inc. - The Woodlands
- Texas Oncology - Waco - Waco
California
- California Cancer Associates for Research and Excellence, Inc. - Fresno
- California Cancer Associates for Research and Excellence - Fresno
- California Cancer Associates for Research and Excellence, Inc. - San Marcos
- St Joseph Heritage Healthcare - Santa Rosa
- St. Joseph Health Medical Group - Annadel Medical Group - Santa Rosa
Other
- LKH Graz - Graz
- Medizinische Universitat Innsbruck - Innsbruck
Colorado
- Rocky Mountain Cancer Centers - Denver - Midtown - Denver
Delaware
- Christiana Care Helen F. Graham Cancer Center - Newark
Maryland
- Rcca Md, Llc - Bethesda
New Jersey
- VA New Jersey Health Care System - East Orange
New York
- New York Oncology Hematology - Albany - Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2019-01-09 |
| Est. Completion | 2022-06-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03679767
The ClinicalTrials.gov registry entry for NCT03679767 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 82-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (48% higher). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Metastatic Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Retifanlimab is the first listed.
NCT03679767 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Texas, California, Other.
Frequently Asked Questions
What is clinical trial NCT03679767 about?
NCT03679767 is a clinical study titled "A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)". The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.
What is the current status of trial NCT03679767?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2019-01-09. Estimated completion is 2022-06-28.
What conditions does trial NCT03679767 study?
This clinical trial studies the following conditions: Metastatic Melanoma, Metastatic Non Small Cell Lung Cancer, Unresectable Melanoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Urothelial Cancer.
What interventions are being tested in trial NCT03679767?
The interventions under investigation include: Retifanlimab (DRUG).
Who is sponsoring clinical trial NCT03679767?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03679767 being conducted?
This trial has 20 study locations across California, Colorado, Delaware, Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
RECRUITING · Phase 2
-
Cryoablation+Ipilimumab+Nivolumab in Melanoma
RECRUITING · Phase 2
-
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
RECRUITING · Phase 2
-
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
RECRUITING · Phase 2
-
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
RECRUITING · Phase 2
Explore more on PlainTrial
Metastatic Melanoma
All registered trials for this condition
Metastatic Non Small Cell Lung Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.